(NEOG) Neogen - Overview

Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 1.892m USD | Total Return: 15.7% in 12m

Stock Food Safety, Animal Safety, Diagnostics, Genomics, Supplies
Total Rating 44
Safety 45
Buy Signal -0.27
Medical Devices -6.2
Health Care Supplies -11.2
Market Cap: 1,892m
Avg Trading Vol: 20.8M USD
ATR: 5.10%
Peers RS (IBD): 93.8
Risk 5d forecast
Volatility56.6%
Rel. Tail Risk-11.1%
Reward TTM
Sharpe Ratio0.40
Alpha-19.82
Character TTM
Beta1.634
Beta Downside1.738
Drawdowns 3y
Max DD81.59%
CAGR/Max DD-0.24
EPS (Earnings per Share) EPS (Earnings per Share) of NEOG over the last years for every Quarter: "2021-02": 0.13, "2021-05": 0.15, "2021-08": 0.16, "2021-11": 0.1, "2022-02": 0.05, "2022-05": 0.14, "2022-08": 0.05, "2022-11": -0.19, "2023-02": 0.04, "2023-05": 0.14, "2023-08": 0.11, "2023-11": 0.11, "2024-02": 0.12, "2024-05": 0.1, "2024-08": 0.07, "2024-11": 0.11, "2025-02": 0.1, "2025-05": 0.05, "2025-08": 0.04, "2025-11": 0.1, "2026-02": 0,
EPS CAGR: -13.19%
EPS Trend: 6.6%
Last SUE: -1.28
Qual. Beats: 0
Revenue Revenue of NEOG over the last years for every Quarter: 2021-02: 116.709, 2021-05: 127.425, 2021-08: 128.305, 2021-11: 130.517, 2022-02: 128.244, 2022-05: 140.093, 2022-08: 132.348999, 2022-11: 230.033, 2023-02: 218.255, 2023-05: 241.81, 2023-08: 228.987, 2023-11: 229.629, 2024-02: 228.812, 2024-05: 236.794, 2024-08: 216.964, 2024-11: 231.258, 2025-02: 220.98, 2025-05: 225.459, 2025-08: 209.189, 2025-11: 224.691, 2026-02: null,
Rev. CAGR: 16.13%
Rev. Trend: 62.2%
Last SUE: 3.45
Qual. Beats: 2
Risks
Technicals: volatile
Description: NEOG Neogen

Neogen Corporation operates in food and animal safety. This includes developing and manufacturing diagnostic tests and related products.

The company has two segments: Food Safety and Animal Safety. The Food Safety segment provides diagnostic kits for detecting contaminants like pathogens, allergens, and toxins in food and animal feed. The food safety industry is driven by increasing regulatory requirements and consumer demand for safer food products.

The Animal Safety segment offers reagents, test kits for toxicology and research, veterinary instruments, and genomics services for livestock and companion animals. The animal health market is experiencing growth due to rising pet ownership and advancements in veterinary care.

To deepen your understanding of Neogens market position, consider exploring its competitive landscape on ValueRay.

Headlines to Watch Out For
  • Food Safety segment revenue growth drives stock performance
  • Animal Safety product demand impacts financial results
  • Regulatory changes in food and animal safety create opportunities
  • Acquisition strategy expands market share and product offerings
Piotroski VR‑10 (Strict) 1.5
Net Income: -602.7m TTM > 0 and > 6% of Revenue
FCF/TA: 0.01 > 0.02 and ΔFCF/TA 2.81 > 1.0
NWC/Revenue: 48.56% < 20% (prev 45.88%; Δ 2.69% < -1%)
CFO/TA 0.02 > 3% & CFO 66.2m > Net Income -602.7m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 3.91 > 1.5 & < 3
Outstanding Shares: last quarter (217.4m) vs 12m ago 0.27% < -2%
Gross Margin: 38.05% > 18% (prev 0.44%; Δ 3.76k% > 0.5%)
Asset Turnover: 23.75% > 50% (prev 22.54%; Δ 1.21% > 0%)
Interest Coverage Ratio: -8.33 > 6 (EBITDA TTM -433.7m / Interest Expense TTM 66.2m)
Altman Z'' -1.09
A: 0.13 (Total Current Assets 574.6m - Total Current Liabilities 147.1m) / Total Assets 3.36b
B: -0.15 (Retained Earnings -516.0m / Total Assets 3.36b)
C: -0.15 (EBIT TTM -551.3m / Avg Total Assets 3.71b)
D: -0.40 (Book Value of Equity -506.8m / Total Liabilities 1.26b)
Altman-Z'' Score: -1.09 = CCC
Beneish M -3.28
DSRI: 0.84 (Receivables 132.0m/164.1m, Revenue 880.3m/913.8m)
GMI: 1.17 (GM 38.05% / 44.35%)
AQI: 0.93 (AQ_t 0.73 / AQ_t-1 0.78)
SGI: 0.96 (Revenue 880.3m / 913.8m)
TATA: -0.20 (NI -602.7m - CFO 66.2m) / TA 3.36b)
Beneish M-Score: -3.28 (Cap -4..+1) = AA
What is the price of NEOG shares? As of April 05, 2026, the stock is trading at USD 9.29 with a total of 1,525,860 shares traded.
Over the past week, the price has changed by +8.16%, over one month by -13.67%, over three months by +29.61% and over the past year by +15.74%.
Is NEOG a buy, sell or hold? Neogen has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy NEOG.
  • StrongBuy: 2
  • Buy: 0
  • Hold: 1
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the NEOG price?
Wallstreet Target Price 11.7 25.6%
Analysts Target Price 11.7 25.6%
NEOG Fundamental Data Overview as of 31 March 2026
P/E Forward = 16.0
P/S = 2.1498
P/B = 0.8993
P/EG = 0.6575
Revenue TTM = 880.3m USD
EBIT TTM = -551.3m USD
EBITDA TTM = -433.7m USD
Long Term Debt = 792.9m USD (from longTermDebt, last quarter)
Short Term Debt = 27.4m USD (from shortTermDebt, last fiscal year)
Debt = 792.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 647.6m USD (from netDebt column, last quarter)
Enterprise Value = 2.54b USD (1.89b + Debt 792.9m - CCE 145.3m)
Interest Coverage Ratio = -8.33 (Ebit TTM -551.3m / Interest Expense TTM 66.2m)
EV/FCF = 147.7x (Enterprise Value 2.54b / FCF TTM 17.2m)
FCF Yield = 0.68% (FCF TTM 17.2m / Enterprise Value 2.54b)
FCF Margin = 1.95% (FCF TTM 17.2m / Revenue TTM 880.3m)
Net Margin = -68.47% (Net Income TTM -602.7m / Revenue TTM 880.3m)
Gross Margin = 38.05% ((Revenue TTM 880.3m - Cost of Revenue TTM 545.4m) / Revenue TTM)
Gross Margin QoQ = 47.48% (prev 34.40%)
Tobins Q-Ratio = 0.76 (Enterprise Value 2.54b / Total Assets 3.36b)
Interest Expense / Debt = 1.87% (Interest Expense 14.8m / Debt 792.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -435.5m (EBIT -551.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.91 (Total Current Assets 574.6m / Total Current Liabilities 147.1m)
Debt / Equity = 0.38 (Debt 792.9m / totalStockholderEquity, last quarter 2.10b)
 Debt / EBITDA = -1.49 (negative EBITDA) (Net Debt 647.6m / EBITDA -433.7m)
 Debt / FCF = 37.66 (Net Debt 647.6m / FCF TTM 17.2m)
Total Stockholder Equity = 2.24b (last 4 quarters mean from totalStockholderEquity)
RoA = -16.26% (Net Income -602.7m / Total Assets 3.36b)
RoE = -26.92% (Net Income TTM -602.7m / Total Stockholder Equity 2.24b)
RoCE = -18.19% (EBIT -551.3m / Capital Employed (Equity 2.24b + L.T.Debt 792.9m))
 RoIC = -14.14% (negative operating profit) (NOPAT -435.5m / Invested Capital 3.08b)
 WACC = 8.70% (E(1.89b)/V(2.69b) * Re(11.73%) + D(792.9m)/V(2.69b) * Rd(1.87%) * (1-Tc(0.21)))
Discount Rate = 11.73% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.23%
[DCF] Terminal Value 67.53% ; FCFF base≈17.2m ; Y1≈11.3m ; Y5≈5.16m
 [DCF] Fair Price = N/A (negative equity: EV 91.0m - Net Debt 647.6m = -556.6m; debt exceeds intrinsic value)
 EPS Correlation: 6.59 | EPS CAGR: -13.19% | SUE: -1.28 | # QB: 0
Revenue Correlation: 62.15 | Revenue CAGR: 16.13% | SUE: 3.45 | # QB: 2
EPS next Year (2027-05-31): EPS=0.32 | Chg7d=-0.097 | Chg30d=-0.037 | Revisions Net=-1 | Growth EPS=-9.3% | Growth Revenue=+1.7%
External Resources
Dataroma Stockcircle